Search BIIB
BIOGEN INC.
Nasdaq · CIK 875045
Last close219.88
Daily change-2.94 (-1.32%)
10 Years gain-29.43%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BIIB · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
37.5Momentum
n/aAcceleration
n/aConfidence
79.0Annual Revenue19
Quarterly Revenue78
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth1.3 / 25
Quality9.4 / 25
Capital Efficiency5.1 / 20
Balance Sheet11.4 / 15
Shareholder Economics8.4 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM3.46%OK
Revenue CAGR 3Y-0.94%OK
Gross Margin74.53%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.57%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $9.89B | $7.49B | n/a | $2.20B | $2.05B | 75.69% | n/a | 20.73% | n/a | 147.1M |
| 2025 FY Dec 31, 2024 | $9.68B | $7.37B | n/a | $2.88B | $2.72B | 76.12% | n/a | 28.13% | n/a | 145.9M |
| 2025 FY Dec 31, 2023 | $9.84B | $7.30B | n/a | $1.55B | $1.27B | 74.24% | n/a | 12.91% | n/a | 145.6M |
| 2024 FY Dec 31, 2022 | $10.17B | $7.90B | n/a | $1.38B | $1.14B | 77.61% | n/a | 11.25% | n/a | 146M |
| 2021 FY Dec 31, 2021 | n/a | n/a | $2.84B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $10.09B | sum latest 4 fiscal quarters Revenue | OK | 0000875045-26-000045, 0000875045-25-000033 |
| Revenue Growth TTM | 3.46% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000875045-26-000045, 0000875045-25-000033 |
| Revenue CAGR 3Y | -0.94% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000875045-26-000013 |
| Revenue CAGR 5Y | -5.96% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000875045-26-000013 |
| Gross Profit CAGR 3Y | -1.76% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000875045-26-000013 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 74.53% | Gross Profit / Revenue | OK | 0000875045-26-000045, 0000875045-25-000033 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000875045-26-000045 |
| Current Ratio | 3.06x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.68x | (Cash + Short-term Investments) / Total Debt | OK | 0000875045-26-000045 |
| Revenue per Diluted Share | $67.99 | Revenue / Diluted Shares | OK | 0000875045-26-000045, 0000875045-25-000033 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0000875045-26-000013 |